Cell Therapy Now Set to Reach More Patients with Expanded FDA Nod for 2 Multiple Myeloma Drugs

The CAR T-therapies Abecma and Carvykti may now be used in earlier lines of treatment for multiple myeloma. The expanded FDA approvals makes these cell therapies more accessible to more patients, broadening the market for both products.